Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment.
Eight onco-developmental proteins have been measured in the serum of women prior to their operation and treatment for ovarian cancer. Alpha-foetoprotein, CEA, hCG and PAPP-A were not often elevated whereas CPAP, SP1, CanAg 50 and CA 125 were. Many of our findings differed from those of previous workers, possibly due to differences in clinical material and analytical technique. We conclude that large profiles of tumour markers are no longer of use in the investigation of ovarian cancer. At the present time we think that CA 125 could prove the most useful marker in the investigation of ovarian cancer.
Pledger
D R
DR
Department of Pathological Biochemistry, Royal Infirmary, Glasgow, U.K.
Belfield
A
A
Kennedy
J H
JH
Kaye
S B
SB
D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis; D014408:Biomarkers, Tumor / Q000097:blood*; D003536:Cystadenocarcinoma / Q000097:blood / Q000175:diagnosis; D005260:Female; D005326:Fetal Proteins / Q000097:blood*; D006801:Humans; D009363:Neoplasm Proteins / Q000097:blood*; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis
D014408:Biomarkers, Tumor; D005326:Fetal Proteins; D009363:Neoplasm Proteins